Marta Boffito

11.4k total citations · 1 hit paper
253 papers, 4.6k citations indexed

About

Marta Boffito is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Marta Boffito has authored 253 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Infectious Diseases, 119 papers in Virology and 87 papers in Emergency Medicine. Recurrent topics in Marta Boffito's work include HIV/AIDS drug development and treatment (163 papers), HIV Research and Treatment (117 papers) and HIV/AIDS Research and Interventions (86 papers). Marta Boffito is often cited by papers focused on HIV/AIDS drug development and treatment (163 papers), HIV Research and Treatment (117 papers) and HIV/AIDS Research and Interventions (86 papers). Marta Boffito collaborates with scholars based in United Kingdom, United States and Ireland. Marta Boffito's co-authors include David Back, Anton Pozniak, Saye Khoo, Graeme Moyle, Brian Gazzard, Akil Jackson, Alan Winston, Andrew Hill, Mark Nelson and Laura Else and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marta Boffito

238 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

2022 162 citations Anton Pozniak, Marta Boffito et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marta Boffito United Kingdom	37	3.4k	2.0k	1.1k	1.0k	628	253	4.6k
Stefano Bonora Italy	34	2.5k 0.7×	1.3k 0.7×	795 0.7×	962 0.9×	456 0.7×	223	3.8k
Richard M. W. Hoetelmans Netherlands	42	4.2k 1.2×	3.1k 1.5×	768 0.7×	949 0.9×	744 1.2×	139	5.2k
Ann Hsu United States	30	3.5k 1.0×	2.7k 1.4×	866 0.8×	531 0.5×	566 0.9×	67	5.0k
Brian P. Kearney United States	40	3.9k 1.2×	2.4k 1.2×	843 0.8×	1.1k 1.1×	589 0.9×	93	5.1k
Gilles Peytavin France	40	4.8k 1.4×	3.7k 1.8×	872 0.8×	1.2k 1.2×	382 0.6×	267	6.3k
Francesca Aweeka United States	40	2.7k 0.8×	1.6k 0.8×	1.1k 1.0×	865 0.8×	800 1.3×	143	5.4k
Heather J. Ribaudo United States	34	3.2k 0.9×	2.4k 1.2×	1.6k 1.5×	658 0.6×	366 0.6×	112	4.4k
Graeme Moyle United Kingdom	44	4.9k 1.4×	3.8k 1.9×	2.4k 2.2×	1.5k 1.4×	363 0.6×	217	6.9k
Catia Marzolini Switzerland	36	3.5k 1.0×	1.9k 1.0×	891 0.8×	950 0.9×	1.3k 2.1×	130	6.0k
Edward P. Acosta United States	49	5.7k 1.7×	4.0k 2.0×	1.1k 1.0×	1.6k 1.5×	884 1.4×	214	8.1k

Countries citing papers authored by Marta Boffito

Since Specialization

Citations

This map shows the geographic impact of Marta Boffito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Boffito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Boffito more than expected).

Fields of papers citing papers by Marta Boffito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Boffito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Boffito. The network helps show where Marta Boffito may publish in the future.

Co-authorship network of co-authors of Marta Boffito

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Boffito. A scholar is included among the top collaborators of Marta Boffito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Boffito. Marta Boffito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geretti, Anna María, Marta Boffito, Stefano Bonora, et al.. (2025). Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. Open Forum Infectious Diseases. 12(7). ofaf368–ofaf368. 2 indexed citations

Quercia, Romina, et al.. (2024). Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review. Infectious Diseases and Therapy. 13(5). 1005–1017. 4 indexed citations

Bracchi, Margherita, et al.. (2024). A case report highlighting drug–drug interactions between 3 life‐saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs. British Journal of Clinical Pharmacology. 90(10). 2383–2386.

O’Brien, Kelly K., Kristine M. Erlandson, Darren A. Brown, et al.. (2024). Episodic disability questionnaire (EDQ) measurement properties among adults living with HIV in Canada, Ireland, United Kingdom, and United States. BMC Infectious Diseases. 24(1). 71–71. 2 indexed citations

Francesco, Davide De, Alan Winston, Patrick Mallon, et al.. (2023). Changes in multimorbidity burden over a 3–5 year period among people with HIV. SHILAP Revista de lepidopterología. 3. 1136999–1136999. 2 indexed citations

Boffito, Marta, et al.. (2023). Tackling late HIV diagnosis: Lessons from the UK in the COVID-19 era. International Journal of STD & AIDS. 35(4). 244–253. 1 indexed citations

Tempestilli, Massimo, Annalisa Mondi, Antonio D’Avolio, et al.. (2023). Pharmacokinetics of tecovirimat in subjects with Mpox. International Journal of Antimicrobial Agents. 63(2). 107068–107068. 3 indexed citations

Boffito, Marta, Rachael Jones, Katrina Stegmann, et al.. (2023). P062 Therapeutic drug monitoring in oral HIV pre-exposure prophylaxis users with a history of bariatric surgery – a case series. A52.2–A53.

Cresswell, Fiona V, Sanjay Bhagani, Marta Boffito, et al.. (2022). UK guideline for the use of HIV post‐exposure prophylaxis 2021. HIV Medicine. 23(5). 494–545. 18 indexed citations

10.

Wasmann, Roeland E., et al.. (2022). Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. Antimicrobial Agents and Chemotherapy. 66(6). e0021522–e0021522. 8 indexed citations

11.

O’Brien, Kelly K., Patricia Solomon, Soo Chan Carusone, et al.. (2022). Assessing the sensibility and utility of a short-form version of the HIV Disability Questionnaire in clinical practice settings in Canada, Ireland and the USA: a mixed methods study. BMJ Open. 12(9). e062008–e062008. 4 indexed citations

12.

Brown, Darren A., Kelly K. O’Brien, Richard Harding, et al.. (2022). Prevalence, severity, and risk factors of disability among adults living with HIV accessing routine outpatient HIV care in London, United Kingdom (UK): A cross-sectional self-report study. PLoS ONE. 17(5). e0267271–e0267271. 5 indexed citations

13.

Herrera, Carolina, Julianne Lwanga, Ming Lee, et al.. (2021). Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). Journal of Antimicrobial Chemotherapy. 76(8). 2129–2136. 9 indexed citations

14.

Bracchi, Margherita, Nicole Pagani, Alessia Dalla Pria, et al.. (2021). A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.. PubMed. 22(5). 128–139.

15.

Kamkwalala, Asante R., Ankita Garg, Upal Roy, et al.. (2021). Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. AIDS Research and Human Retroviruses. 37(11). 807–820. 3 indexed citations

16.

Vera, Jaime H., Margherita Bracchi, Jasmini Alagaratnam, et al.. (2019). Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART. Brain Sciences. 9(8). 195–195. 14 indexed citations

17.

Jackson, Akil, Laura Else, Christopher Higgs, et al.. (2017). Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals. HIV Clinical Trials. 19(1). 31–37. 4 indexed citations

18.

Rockwood, Neesha, M Nelson, S Mandalia, et al.. (2011). A comparative analysis of risk factors associated with efavirenz, darunavir/ritonavir, lopinavir/ritonavir, atazanavir/ritonavir and renal impairment. HIV Medicine. 12. 1–1. 3 indexed citations

19.

Else, Laura, Akil Jackson, Rebekah Puls, et al.. (2011). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. Antimicrobial Agents and Chemotherapy. 56(3). 1427–1433. 28 indexed citations

20.

Lamorde, Mohammed, Pauline Byakika‐Kibwika, John P. Flaherty, et al.. (2010). Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women. JAIDS Journal of Acquired Immune Deficiency Syndromes. 55(3). 345–350. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact